|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04010210
|
13-epi-13-D4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2R,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010335
|
13-epi-13-E4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2S,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010338
|
13-epi-13-E4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2R,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010265
|
13-epi-20-D4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,5S)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010264
|
13-epi-20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,5S)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010393
|
13-epi-20-E4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,3R)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010392
|
13-epi-20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010231
|
14-D4c-NeuroP
|
(Z)-6-((1R,2S,5S)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010234
|
14-D4t-NeuroP
|
(Z)-6-((1S,2R,5S)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010359
|
14-E4c-NeuroP
|
(Z)-6-((1R,2S,3R)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010362
|
14-E4t-NeuroP
|
(Z)-6-((1S,2R,3R)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010227
|
14-epi-14-D4c-NeuroP
|
(Z)-6-((1R,2S,5S)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010230
|
14-epi-14-D4t-NeuroP
|
(Z)-6-((1S,2R,5S)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010355
|
14-epi-14-E4c-NeuroP
|
(Z)-6-((1R,2S,3R)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010358
|
14-epi-14-E4t-NeuroP
|
(Z)-6-((1S,2R,3R)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010217
|
16-epi-13-D4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2S,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010216
|
16-epi-13-D4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2R,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010345
|
16-epi-13-E4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2S,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010344
|
16-epi-13-E4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2R,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010247
|
17-D4c-NeuroP
|
(4Z,7Z)-9-((1R,2S,5S)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010250
|
17-D4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,5S)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010375
|
17-E4c-NeuroP
|
(4Z,7Z)-9-((1R,2S,3R)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010378
|
17-E4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,3R)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010243
|
17-epi-17-D4c-NeuroP
|
(4Z,7Z)-9-((1R,2S,5S)-5-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010246
|
17-epi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,5S)-5-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010371
|
17-epi-17-E4c-NeuroP
|
(4Z,7Z)-9-((1R,2S,3R)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010374
|
17-epi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,3R)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010263
|
20-D4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,5S)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010266
|
20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,5S)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010391
|
20-E4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3R)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010394
|
20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010259
|
20-epi-20-D4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,5S)-5-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010262
|
20-epi-20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,5S)-5-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010387
|
20-epi-20-E4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3R)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010390
|
20-epi-20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3R)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010193
|
4,11-diepi-11-D4c-NeuroP
|
3-((1S,2S,5R)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010192
|
4,11-diepi-11-D4t-NeuroP
|
3-((1R,2R,5R)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010321
|
4,11-diepi-11-E4c-NeuroP
|
3-((1S,2S,3S)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010320
|
4,11-diepi-11-E4t-NeuroP
|
3-((1R,2R,3S)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010145
|
4,7-diepi-4-D4c-NeuroP
|
(R,E)-4-hydroxy-6-((1S,2S,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010144
|
4,7-diepi-4-D4t-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2R,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010273
|
4,7-diepi-4-E4c-NeuroP
|
(R,E)-4-hydroxy-6-((1S,2S,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010272
|
4,7-diepi-4-E4t-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2R,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010151
|
4-D4c-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2S,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010154
|
4-D4t-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2R,5S)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010279
|
4-E4c-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2S,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010282
|
4-E4t-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2R,3R)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010201
|
4-epi-11-D4c-NeuroP
|
3-((1S,2S,5S)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010200
|
4-epi-11-D4t-NeuroP
|
3-((1R,2R,5S)-5-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010329
|
4-epi-11-E4c-NeuroP
|
3-((1S,2S,3R)-3-hydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|